Healthcare News 2

• "Not your Father's Cataract Surgery Anymore": New IOLS Correct Distance and Near Vision
• "Short term" results indicate Drug eluting stents are safe for use in acute MI
• ? An Artificial Crisis?
• 3-Drug Anti-HIV Regimen for HIV-infected patients without TB
• a $74,340 Dollar a year pill?
• A clinician's view
• A combo therapy fails but others are pending
• A Comparison of Epidemiological and Biostatistical Analyses
• A cure for shingles?
• A new antifungal option
• A new missile - possibly a redundancy ????
• A new powerful combination therapy for hypertension: valsartan & amlodipine
• A Potential Increase in Diagnosed Heart Attacks – A Growing Market?
• A solution to primary care-no silver bullet
• A Specific Chemical In Bausch & Lomb's ReNu with MoisturLoc Is Identified and Linked to Fusarium Keratitis Outbreak
• ABIOCOR - SELF-CONTAINED, IMPLANTABLE ARTIFICIAL HEART
• AbioCor? Close, but no cigar.
• Acceptance of HPV vaccine
• Accommodative IOL Moves Forward
• Acomplia (Rimonabant) - A fait accompli ?
• ACP-103 for psychosis of Parkinson's disease
• Actos and an ARB: Not an optimal combination
• Acute MI and Late Thrombosis
• Addicted to food--looking for Bacchus in all the wrong places
• Additional observations on Wal-Mart's generic pricing move
• ADHD treatment
• ADHD treatment with Stimulant drugs and current FDA warning
• Aetna Vs. CIGNA MLR
• After Fungal Keratitis Scare (Caused by Bausch & Lomb's ReNu with MoisturLoc), Contact Wearers Want to Know Which Contact Lens Solutions Are Safe
• Alimta vs Taxotere in Seniors: Lilly Wins?
• Alternative drug treatment of HIV
• American Law Firms Represent "ReNu Victims" From Asia, U.S., and Abroad In Lawsuit Against Bausch & Lomb
• Amgen should have no concerns about competition for anemia management products for a while
• An Uphill Battle Against Reimportation?
• Analysis of diuretic risk in Heart failure
• Analysis of NEJM Articles on DES in MI
• Another beneficial combination antihypertensive with nephrologic benefit
• Another marker for Alzheimer's disease
• Another Usw for Revlimid
• Another Vioxx?
• Antibiotics and Runny Noses
• Applicability of this device
• Are ACE Inhibitors Better than ARBs?
• Are Gene Therapy Products Commercially Sustainable?
• Aroxia Will Not Relieve Merck's Headache
• Artificial joint sales on the rise
• Assessment of Toll-Like Agonists in Hepatitis C
• Asthma Management: Another Form of Gender Bias?
• Asthmatic smokers who quit see a 15% improvement in lung function at 6 weeks
• Avastin a Dud in Pancreatic Cancer: ho-hum news
• Avastin and the age-related macular degeneration
• Avastin Holds Great Promise as a Cheap an Effective Treatment but its Further Use May by Many Other Factors
• Avastin in treatment of pancreatic cancer surprise or expected
• Avastin needs multiple cytotoxics
• Avastin Remains strong
• Avian Influenza Transmission
• Baraclude: a hepatitis B drug with high potency and no resistance at 2 years
• Bausch & Lomb Releases the First Silicone Hydrogel Multi-Focal Contact Lens
• Bausch & Lomb's Shares Have Lost More Than Half Their Value Since July 2005
• Benefits vs drawbacks of this preparation
• Beta Blockers ? - Not for hypertension
• Big Win for GSK Could Bring Fee-for-Service to Europe
• Bioglue: Another indication strikes again
• Bivalirudin for PCI in ACS
• Blood Substitute Trial Finishes At Last - What Next?
• BMS also lost control of oncology distribution
• Bortezomib treatment for relapsed mantle cell lymphoma
• Botox & Facial Scarring: Interesting Niche Application
• Bottom line on DES and AMI
• BREAKING NEWS: FDA Approves Lucentis For Wet Age-Related Macular Degeneration
• Bristol Myers CEO and Plavix Controversy
• Broad Implications of Improved Lung Function in Asthmatic Patients Who Quit Smoking
• Can an old dog learn new tricks??
• Can Violence Come from a Calming Agent?
• Can we afford the AbioCor?
• Cancer treatment centers suffer for lack of volunteers
• Cardiac warnings on ADHD drugs not likely to decrease market share
• Cautious optimism for Galxo's "breakthrough" avian flu vaccine.
• CCR5 antagonists: New Data
• CDH: Lower Costs Through Higher Generic Dispensing Rates
• CDHP and Large Employer Market
• CDHP not Replacement of HMO/PPO
• Cefotaxime
• Cefotaxime's rebirth not likely to change prescribing patterns
• Ceftriaxone is still the main antibiotic for IM/IV outpatient management of most infections
• CELACADE DISAPPOINTS IN ACCLAIM TRIAL: IS THIS THE END FOR ANT-INFLAMMATORY TREATMENT OF HEART FAILURE
• Cephalon Reverses Course: Pulls Plug on Sparlon
• Cervical Cancer Shots Covered or Not Covered
• Cervical Cancer vaccine vs. Lopinavir
• Changes will affect different stakeholders differently
• Changing the Rules mid-Game: FDA and Oncotype Dx
• Chasing Ghosts
• Cheaper clopidogrel to be widely used-Plavix in the Crosshairs of Formularies
• Clinical confusion
• Clinical Diagnostics Based Upon Predictive Statistical Probability
• Clinical effects of Rosiglitazone (Avandia) in Alzheimer's disease
• Clinical Success of The Emperion Modular Hip System
• Clinical trial of DAC(TM):GRF led to fatal outcome connecting to serious regulation of metabolism in human
• Clinical trials: Why such few takers?
• CMS and reimbursement decisions
• CMS BROAD BRUSH COVERAGE ISSUES
• Combination antihypertensives - An old, new trend
• Combination of pioglitazone and ACEI by Takeda
• Combination therapy of budesonide & formoterol for asthma gives new alternative but is likely to be limited by its delivery system
• Competition for Intralase: Real or Hype?
• Competition is for patients failing to respond to vaccination
• Competition starts with a 25% reduction in the price of Clopidogrel
• Concern that this is just the beginning
• Concerns for Drug eluting stents (DES)
• Constipation is a major complication of chronic opioid treatment
• Coopervision Confirms Launch of Silicone Hydrogel
• Coopervision Has Pushed Back Its Scheduled U.S. Launch of Its Silicone Hydrogel Contact Lense (Biofinity) to December
• Coopervision Opposes Proposed Legislation that Requires Contact Lens Manufacturers to Sell to Poorly Regulated and Unsafe (Online) Retailers
• Coronary Heart Disease as a Predictor for Impotence
• COX - 2 albatross
• Crisis in medicare reimbursements
• Crowded Field of OAB Medications
• C-Sections confirmed (again) to be more risky
• Cutting Doctors Fees Would be Disastrous
• Cypher & Taxol Drug Eluting Stents placed acutely post MI
• Daptomycin - use in bacteremia
• Daptomycin. A one hit wonder?
• Darunavir (TMC114, Prezista)
• Dasatinib (BMS): A TYrosine Kinase Inhibitor With a Difference
• Dasatinib (Sprycel, BMS)Approved!!
• Daytrana - a new option for ADHD in extended-day schoolchildren
• Deja Vu all over again
• Delay in sBLA of Limited Significance
• DES – revascularization method of choice in AMI
• DES and MI and late stent thrombosis
• DES and STEMI
• DES in Acute MI
• DES in AMKI
• DES in MI
• DES in MI
• DES in MI
• DES in MI
• DES in MI, DES and risk Thrombosis.
• DES in MI: Votes Not In
• DES is safe and effective in AMI intervention.
• DES- Not all that glitters is gold
• DES usage in AMI
• DES use
• DES Zenith - Efficacy or Cost
• DES: where do we and don't we stand?
• Diagnostics-Therapeutics: Where is the money?
• Diagnostics-Therapeutics: Where's the money? Part II
• Did Dolan Understand the Oncology Franchise
• Disease Management ROI Difficult To Quantify
• DNAPrint Genomics "Super EPO": New Competition for Amgen on the Horizon!
• doctors and medicare
• DOCTORS HAVE AN OPTION
• Does Efaproxiral Appeal to the Sensitivity of Oncologists?
• Does Genasense Make Sense?
• Don't Forget Benefit Buydowns When Analyzing Premium Increases
• Drug coated coronary stents in acute myocardial infarction-need for longer followup.
• Drug coated stents or Bare Back?
• Drug eluting stent failure rate
• Drug Eluting Stents in acute MI
• Drug eluting stents in MI: time for full metal jackets?
• Drug Eluting Stents Safe in AMI
• Drug industry trying to stop drug price regulation with PR
• Drug Injected Into the Eye Is Shown to Improve Vision Loss from Macular Degeneration
• Drug-Eluting Stents in MI
• Drug-eluting stents may take a hit
• Drug-eluting Versus Uncoated Stents
• E4D -- Competition for CEREC Dental Restorations?
• ED and cardiovascular disease are linked
• Effective vaccine against avian flu has been announced, but something is unclear
• Effective, "expensive" , emerging market
• E-health reality or fiction
• Elective Surgery May Prove To Be A Popular Avenue For This Drug
• Electronic medical records are a necessity, not a luxury
• Electronic Medical Records Save Lives- But Who Will Pay
• Enormous potential of Rimonabant- Effect on the adipocyte
• Erectile dysfucntion and cardiovascular risk: A possible link
• Erectile dysfunction could lead to earlier diagnosis of cardiac disease
• Erlotinib: How much more efficacy do we need to see?
• ETHICON/OMRIX and ZymoGenetics Neck-and-Neck in Race to Thrombin Market
• Extended release is a good gimmick, but no less addictive
• Failure of fourth line treatment of depression could lead to increased use of psychotherapy and mental health services
• FDA and Oncotype
• FDA approval of Lavipharm's patch sets a trend to be followed by foreign pharmaceutical companies.
• FDA Nano Task Force, Good or Bad?
• FDA request for more data not unusual but adds delays
• financial implications
• first confirmed case of transmission bird flu from human to human but not unusual
• Flawed Medical Care Reimbursement
• Florida pedigree change is good for drug wholesalers
• Flu vaccines for 2006-7 season do not include Avian flu protection
• Fodosine is a promising drug for refractory and relapsed T-cell Lymphoma/Leukemia
• FTC Cracks Down on Internet Marketers That Sell Cosmetic Contact Lenses (Illegally) Without a Prescription
• Future of DES
• Gaboxadol: Teaching an old receptor new tricks?
• Gardasil - do most parents REALLY debate its use?
• Gardasil and Merck should dominate the market
• Genasense Helps Some with CLL but Will Not Help Genta
• Genasense Running on Empty
• Genentech and Biotechs future......
• Genentech Spurned?
• Generalizing superiority of nexium over prevacid in maintaining healed erosive esophagitis to the treatment of GERD
• Generic clopidogrel - boon for insurers but little help for patients
• Generic clopidogrel not likely to improve compliance
• Generic clopidogrel should not alter its use
• Generic Clopidogrel: A No-Brainer?
• Generic Clopidogrel: A Boon to Patients and Providers
• Generic Fentanyl a Welcome Addition
• Generic Fentanyl Patches given general thumbs up
• Generics--fool me once, but......
• Genomics and BiDil – Future Hope
• Genta Genuflects
• Gleevec (Novartis) Heart Damage??
• Great Concept But Who Will Pay The Price?
• great possibilities
• Hepatitis B - new prospects of treatment: Baraclude instead of Epivir-HBV
• Herceptin: a mixed blessing? Not really, it just requires care in administration
• Here comes the collapse...
• Higher dose COPAXONE offers promise for patients with /relapsed MS but the field is getting crowded
• HIPAA strikes again!
• Hold the Presses! A Stumbling Block for Genentech and Roche??
• How Much Can You Cut the Food Allocation Until the Animal Starves?
• How will your electronic prescribing system talk to mine?
• Human Genetic Susceptibility to Avian Influenza
• Humanized Anti-CD22 Antibody, Epratuzumab: a new player in lymphoma world?
• HYPERTENSION AND HYPERCHOLESTEROLEMIA – STILL AN UNMET MEDICAL NEED AND GROWTH OPPORTUNITY
• I Don't Think So !
• I have seen this in my practice
• IF you pay peanuts you get Monkeys
• IgA not a useful therapeutic, but mucosal vaccination could be
• Impact of generic clopidogrel
• Impact of renin inhibitor and ARB-CCB combo across the cardiovascular continuum
• Implantable Miniaturized Telescope Goes Before FDA
• Implications of a generic Fentanyl Patch
• Impotence and heart disease
• Impotence as a Marker for Heart Disease
• Inappropriate antibiotic use
• Indications for Pulmonary Artery Catheter
• Innovations in Cataract Surgery Drive Growth in Ambulatory Surgery Centers
• INTEREST IN A NEW LASER EYE PROCEDURE SUPPORTED BY LASTEST STUDY IN JOURNAL OF REFRACTIVE SURGERY
• Interesting, but nothing more
• Internet Health will guide the future
• Interpretation of Meta-Analyses
• INTRALASE USEFUL FOR MORE THAN JUST LASIK
• Intravenous Immunoglobulin (IVIG) - Encouraging Early Results in Alzheimer's Disease
• IRRELEVANT FDA TECHNICALITIES
• Is Quetiapine an "easy fix"
• IT Is Not What It Appears To Be
• IT re-think worth a thought
• It's all about marketing!
• Its Deja Vue All Over Again
• Kaletra losing its position as the "gold standard" protease inhibitor
• Keep an eye on Medicare "Direct Negotiations" movement
• Ketamine treats depression within 2 days but with abuse potential and possible serious side effects
• KISS
• Known cause of macular degeneration?
• Kudos to Buffett; Gates Foundation should focus on HIV
• Large Group vs. Small Group market is very different
• LASIK IS NO LONGER THE SOLE REFRACTIVE PROCEDURE OFFERED PATIENTS
• Latest Report Reveals Bausch & Lomb Allegedly Knew About ReNu w/ MoisturLoc's Link to Fusarium Keratitis a Month and a Half Before They Reported It
• Law Firm Calls Upon Bausch & Lomb to Recall ALL ReNu Contact Lens Solutions
• Less is more
• Like all new vaccines, FDA approval precedes insurance coverage
• Lilly continues to present old data on Ruboxistaurin
• Limited diapason for using of live, attenuated intranasal H5N1 vaccine is not a very good perspective for it development
• Limited human-H5N1 to-human transmission documented
• Local School Boards Begin Weighing in on Gardasil
• Lopinavir role in cervical HPV treatment still at earliest stage
• Lucentis Approval Was Expected
• Lucentis gains FDA approval for treatment of Age-related Macular Degeneration
• Macular degeneration: A new market for multifocals lenses?
• Mantle cell NHL Popularity
• Many potential uses for rituximab will likely fuel its market growth
• Medco Agrees to a More Transparent Business Model
• Medical errors common but avoidable with technology
• Medicare cuts
• Medicare cuts risk worsened patient outcomes
• Medicare Cuts Will Discourage Use of New Technology
• Medicare is Creating a Specialist Shortage in Rural America
• medicare pay cuts
• Medicare Prescription Drug Plan Unworkable in LTC
• Medicare reimbursement cuts will compromise patients access to care
• Medication errors can be decreased by electronic prescribing
• Medication errors will be decresed by electronic prescribing
• MedImmune resubmits FluMist application for easier storage and younger patients
• MedImmune to submit improved nasal flu vaccine for approval
• Medimmune won't get help in melanoma either
• MedImmune's prospects diminish with only 2 products to sell this year
• Merck becomes the vaccine maker to beat
• Merck has another big seller
• Merck may have a winner!
• MERCK Vaccine will prevent Cervical CA but ALSO Dysplasia and invasive procedures affected FERTILITY
• Merck's other vaccine success story
• Misunderstanding of Impact
• Mixing Multifocal Intraocular Lenses: Fad or Future
• MK-0518 and expanded access approval
• MK-0518 looks like a winner.
• Morning-After Pill Almost Guaranteed This Time Around
• Multifocal LASIK: Is it ready for prime time?
• NEJM: Use of DES post Acute MI
• Neurochem provides scientific support for its product Alzhemed
• New COX-II inhibitor not a likely winner
• New FDA Warnings will not impact ADHD prescribing patterns
• New information in WSJ on contact lens solutions.
• New Sports Contact Lenses by Baush & Lomb and Nike Are Said to Enhance Vision and Performance
• New studies suggest DES may improve outcome in the setting of AMI
• New Therapy for Non Small Cell Lung Cancer (NSCLCA)
• New treatment for wet macular degeneration
• New warnings may drive market shares of Dexedrine even lower
• Nexium is better than Prevacid in Maintaining Healed Erosive Esophagitis
• NHS IT Program too unwieldy
• No antibiotics for colds is old news in U.S.
• No Benefits to 4 drugs over 3 in Treatment
• No Change in Use of Quetiapine Expected
• no free lunch
• Non-glycemic benefits of Rosigliatazone: too little to late?
• Not reflective of current trend
• Not Significant - Yet
• Observation of slightly increased risk of violence with antidepressants
• Ocular safety of Rosiglitazone
• Odds Are, Avian Flu Will Be A Flop
• Of Mice and Men: Revisiting the Hygiene Hypothesis
• Oh Oh, here we go again!
• Once daily therapy for opiate induced constipation starting phase II trial
• once per day keeps the competition away
• Once weekly Exenatide LAR is a promising medication for diabetes and obesity
• Once weekly exenetide allows greater than 80% of diabetics to reach A1C goal
• Oncologists continue to hurt for effective therapy for MCL
• Oncotype Dx - unavailable to most - FDA might change that
• Onercept (TNF Binding Protein 1) is Ineffective in the Treatment of Moderate-to-Severe Crohn's Disease
• Ongoing use of DES in acute MI and otherwise
• Opposition to Gardasil HPV vaccine confined to fringe, religious groups
• Ousted CEO
• Outpatient medication errors are now being tallied.
• Pancreatic cancer and Avastin- not a good match
• Part D Not Perfect But Better Than No Drug Plan
• Patient privacy a litttle overboard
• Payment for Gardasil Elusive for some
• Percutaneous valve replacement: Are we there yet?
• Peter B Davis FACHE
• Pharmacological therapy for HPV: new hope and many questions
• Pharmacy Copay Trends in Employer Benefit Plans
• Physician order entry would eliminate transcription error
• Physician Reimbursement Cut Not Necessarily Dire
• Pick your complication
• Pipex Therapeutics Studies Tetrathiomolybdate as a Treatment for Alzheimer's Disease and Cancers
• Plenty of Gardasil
• Plenty of Room For Melanoma Treatments
• Politics trumps facts in reimportation debate
• Potential Impact of Electronic Medical Records
• Potential Increased Use of Botox
• Potential new diagnostic marker for macular degeneration
• Preferred Techniques around the Ophthalmic World: LASERS and IOLS
• Prevention of Cervical Cancer
• Primary care will be especially effected..
• Privacy + Security = Increased Profits
• Privacy Nice at What Price?
• Privacy of Patients is important, but....
• Proprietary testing based on software will be subject to regulation
• Pulmonary Artery Catheterization - A Dying Procedure
• Purchasers now questioning Health Management ROI Claims
• Quetiapine and Borderline personality disorder
• rapa- rapa- AHP?
• Rare NHL treatment
• Rare, Yes. Profitable? You Tell Me.
• Real perspectives for prevention WNV infection
• reimbursement for spine surgery
• Retail commercial medical clinics
• Return of Azacytidine? Striking back at Revlimid.
• Rising Costs
• RISK OF NON-POTASSIUM-SPARING DIURETICS IN HEART FAILURE: IS OPPORTUNITY KNOCKING?
• Rite-Aid + Brooks-Eckerd: Will three wrongs make it Rite?
• Rituxan holds promise in treatment of MS , but has to catch with Campath
• rituxan in the future
• Rituxan is the "crown jewel" of Genentech's in-line drugs
• Rituxan will rule, but for how long?
• Rosiglitazone (Avandia) for the Treatment of Alzheimer's Disease
• Rosiglitazone (Avandia) shows efficacy in the treatment of Alzheimer's Disease
• Rules may help Community Physicians
• Safety of PolyHeme
• safflower-derived insulin
• Sales of new drugs for macular degeneration will not be affected by inflammation-gene variant linkage
• Sargramostim (GM-CSF) - An Alternative Biological to Remicade (infliximab) in the Management of Crohn's Disease?
• Silicone Hydrogel Contact Lenses and the Future of Coopervision
• Silicone Hydrogel Contact Lenses Are Nice, But Are They for Everyone?
• Simple potent and safe. This HIV combination will be hard to beat.
• siRNA Gene Therapy open new skylines for HIV-infection
• Size Matters
• Sleep Apnea and Stroke
• Solx, Inc. is Acquired by Occulogix, Inc.
• Sparlon - not for ADHD
• Spine Fusion Coverage Will Not Be Denied
• sprycel helps a little
• SSRI antidepressants should not be prescribed like water
• Stent Thromboses
• Stent thrombosis, DES in MI
• Stents - More, Better, "New and Improved", "Super Special" - What does it matter?
• STENTS - SAFE AND HERE TO STAY
• Stop beating a dead horse...
• Strength of supermarket pharmacies is good for drug wholesalers
• Strict control of hypertension will markedly lower stroke incidence and save billions
• Study in Miami Shows Increase in Contact Lens Related Fungal Keratitis
• Study Shows Most Patients That Contracted Fusarium Keratitis Also Had Poor Contact Lens Hygiene
• Study suggest new drug designs
• Survey Shows Patients Are Willing To Pay More for Increased Contact Lens Comfort
• Symbicort approved; Will it take off? Will it knock off Advair?
• Tarceva Not the Answer for Pancreatic Cancer
• Tarceva to the Rescue?
• Tetanus vaccination has an immunomodulatory mechanism that may lower or delay the risk of developing Multiple Sclerosis
• The Changing Landscape of Clopidogrel
• The costs of privacy
• the crowded epo market
• the doctor is out
• The Doctors Are Leaving
• The dreaded start of Human to Human Pandemic Flu transmission? - Well not probably
• The future of heart failure therapy
• The Future of Low Grade Lymphoma Therapy
• The impact of generic Plavix (clopidogrel)
• The impact of the study of using DES in acute MI.
• The Importance of a Preventative Vaccine for Shingles
• The Importance of Botox to Reduce Facial Scarring
• The jury is still out
• The mouse is already in the house...
• The non-relevence of simple, transdermal drug delivery.
• The old strategy is back, are we ready
• The Stent Used in Acute Myocardial Infarction does not matter.
• The triple pill isn't a panacea. But it can find its patient.
• The Velcade story continues to build...
• There Are Now Three Femtosecond Players
• There is already too much treatment and misdiagnosis of ADHD--this may cause a called for "adjustment"
• There is hope for smokers - Quit now!
• There is no such thing as a free lunch......?
• Thrombosis and drug eluting stents in MI.
• Title: DES in Acute MI. DES in general
• TK inhibitors- WMD's (Weapons of Mass Destruction?)
• To Prophylax? or not to Prophylax?
• Too LIttle Support for Clinical Trials
• Too little too late
• Torcetrapib markedly elevates HDL-cholesterol & may be combined with statins to further lower incidence of cardiovascular disease
• Torcetrapib: Impact on LDL and HDL Therapy
• Torsional phacoemulsification: The next advance in cataract removal technology
• Tramadol er
• Tramadol ER likely to take significant market share from Ultram ER
• Transapical Valve replacement - A different "Less invasive" technique
• Treament interruptions in HIV therapy
• Treatment of air leaks in pulmonary surgery
• Treatment of HIV infected patients
• Trospium is another option for treating overactive bladder
• Trospium struggles in the face of a fast market
• Trospium will not become the standar of care for the treatment of overactive bladder
• TVT, a not so new procedure
• UK Difficulties with Developing National Health IT Infrastructure
• UK Healthcare electronic interconnection System
• Understanding the reimportation debate
• Unique formulation leads to keratitis in contact lens solution
• Update on ADHD drugs
• Upper respiratory tract infections, antibiotics, and vaccinations
• US Preventative Task Force Guidelines
• use of Baraclude
• Use of current generation Drug eluting stents will decline in markets with high penetration
• Use of DES in AMI supported
• Use of DES to decrease
• Useful for surveillance rather than clinical practice
• User friendly IVUS
• Vaccine for Bird Flu
• Vaccine strategy unlikely to work for treatment for metastatic breast cancer
• Vaccines have yet to treat cancer
• Vaptans (V2 receptor antagonists): new agents in the management of hyponatremia and polycystic kidney disease
• Vaptans (V2 receptor antagonists): new agents in the management of polycystic kidney disease
• Velcade has promising efficacy in relapsed Mantle Cell Lymphoma.
• Velcade in lymphoma?
• Velcade use expands
• Velcade: The Immediate Future for Mantle Cell NHL
• Velcade: More & More Weekly!
• Violent behavior risk of Paxil not likely to influence market share
• Vision Care's Implantable Miniature Telescope Approval Delayed
• Vitamin "R" Strikes Again?
• Vitamin R?- Rituximab
• Waiting for Version 2.0
• Walmart MD
• Wal-Mart's generic pricing will reshape pharma distribution
• Warning: You Get What You Pay For!
• Wavefront Guided PRK can Produce Excellent Outcomes in Patients not suitable for LASIK
• What DOES work for runny noses
• What is the Personal Cost of Innovation
• Where are all the STEMIs gone?
• Why Reinvent the (Growth Receptor) Wheel in Pancreatic Cancer
• Why women are more often admitted for asthma
• Will all adults over 60 get this vaccine?
• Will approval of toric phakic IOLs change the refractive surgery landscape?
• Will Epirubicin (Pfizer) Rise from Obscurity?
• Will expanding applications of femtosecond lasers help growth?
• Will improvements in surface ablation techniques erode LASIK popularity?
• Will Trospium(Sanctura XR) gain market share?
• Winners and Losers in the Zocor Wars
• Winning Cancer Drug Pipeline for Genentech
• With the Millions of Refractive Surgery Patients, Are the Number of Contact Lens Wearers Declining?
• Wither cervical cancer?
• You Don't Have to be a STAR, Baby
• Zostavax - Future in CMS/CDC's Hands
• ZymoGenetics' rhThrombin -- On a Collision Course with the Competition